Thermal Ablation for Benign Thyroid Nodules and Papillary Thyroid Microcarcinoma.

IF 0.8 Q4 SURGERY
Daqi Zhang, Hui Sun, Anna Maria Ierardi, Salvatore Alessio Angileri, Francesco Frattini, Simone Mortellaro, Arianna Ceriello, Jerry Spisani, Gianluca Donatini, Gianlorenzo Dionigi, Giampaolo Carrafiello
{"title":"Thermal Ablation for Benign Thyroid Nodules and Papillary Thyroid Microcarcinoma.","authors":"Daqi Zhang, Hui Sun, Anna Maria Ierardi, Salvatore Alessio Angileri, Francesco Frattini, Simone Mortellaro, Arianna Ceriello, Jerry Spisani, Gianluca Donatini, Gianlorenzo Dionigi, Giampaolo Carrafiello","doi":"10.52198/24.STI.44.GS1806","DOIUrl":null,"url":null,"abstract":"<p><p>Ultrasound-guided minimally invasive thermoablative (MIT) therapies are a therapeutic option for selected patients with large, hypoenhancing, benign thyroid nodules that cause compression disorders or aesthetic discomfort. MIT, which does not require general anaesthesia, causes thermal necrosis of the treated nodule, which is reduced in size by 50 % without functional consequences, and is indicated for patients who are not too young or in the presence of anaesthesia-related risk factors or recurrence following thyroidectomy or refusal of surgery. For the above indications, MIT complements surgery but does not replace it; it must always be performed in centres and by surgeons with proven technical skills and clinical experience. Subject to appropriate informed consent, the treatment is short-duration, well-tolerated by the patient, safe, and non-invasive. It does not require anaesthesia and complications are rare and transient. MIT, and in particular laser-based procedures (TAL), can also be effective and safe for the treatment of potentially destructible papillary microcarcinoma, as shown by the limited but sufficient literature, including the most recent guidelines, which consider it to be a therapeutic alternative that requires a better understanding of its efficacy and safety.</p>","PeriodicalId":22194,"journal":{"name":"Surgical technology international","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical technology international","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52198/24.STI.44.GS1806","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Ultrasound-guided minimally invasive thermoablative (MIT) therapies are a therapeutic option for selected patients with large, hypoenhancing, benign thyroid nodules that cause compression disorders or aesthetic discomfort. MIT, which does not require general anaesthesia, causes thermal necrosis of the treated nodule, which is reduced in size by 50 % without functional consequences, and is indicated for patients who are not too young or in the presence of anaesthesia-related risk factors or recurrence following thyroidectomy or refusal of surgery. For the above indications, MIT complements surgery but does not replace it; it must always be performed in centres and by surgeons with proven technical skills and clinical experience. Subject to appropriate informed consent, the treatment is short-duration, well-tolerated by the patient, safe, and non-invasive. It does not require anaesthesia and complications are rare and transient. MIT, and in particular laser-based procedures (TAL), can also be effective and safe for the treatment of potentially destructible papillary microcarcinoma, as shown by the limited but sufficient literature, including the most recent guidelines, which consider it to be a therapeutic alternative that requires a better understanding of its efficacy and safety.

甲状腺良性结节和甲状腺乳头状微癌的热消融术
超声引导下的微创热消融(MIT)疗法是一种治疗方法,适用于患有大的、低增强的、良性甲状腺结节并导致压迫障碍或美观不适的特定患者。热疗疗法不需要全身麻醉,治疗后结节会出现热坏死,结节会缩小50%,但不会对功能造成影响,适用于年龄不大、存在麻醉相关风险因素或甲状腺切除术后复发或拒绝手术的患者。对于上述适应症,MIT 是对手术的补充,但不能取代手术;MIT 必须始终在中心进行,并由具备成熟技术和临床经验的外科医生实施。在获得适当知情同意的情况下,该疗法持续时间短、患者耐受性好、安全且无创。它不需要麻醉,并发症很少,而且是一过性的。MIT,尤其是激光治疗术(TAL),也可以有效、安全地治疗潜在的可破坏性乳头状微癌,这一点已在有限但充分的文献中有所体现,包括最新的指南,指南认为这是一种替代疗法,需要更好地了解其疗效和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.00
自引率
0.00%
发文量
141
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信